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Background: Fluticasone furoate (FF)/vilanterol (VI) 100/25 mcg is a once-daily inhaled corticosteroid (ICS)/
long-acting beta2 agonist (LABA) treatment approved in the United States, Canada and Europe for the long-term
maintenance therapy of COPD. We report data from mixed treatment comparisons (MTC) of once-daily FF/VI against
established twice-daily ICS/LABA combination therapies on clinical efficacy outcomes.
Methods: Data from 33 parallel-group randomised controlled trials (RCTs) of ICS/LABAs, of ≥8 weeks’ duration in
patients ≥12 years of age with COPD, identified by systematic review, were analysed using covariate-adjusted
Bayesian hierarchical models for three efficacy outcomes. Lung function, assessed by change from baseline in
forced expiratory volume in one second (FEV1), was the outcome of primary interest (n = 28 studies). Secondary
objectives were assessment of annual rate of moderate/severe exacerbations (n = 15) and patient-reported health
status, measured by change from baseline in St George’s Respiratory Questionnaire (SGRQ) Total score (n = 20).
Overall, 25 different treatments were included in the MTC; we report findings, including probabilities of non-inferiority,
for comparisons of once-daily FF/VI 100/25 mcg with twice-daily fluticasone propionate (FP)/salmeterol (SAL) 500/50 mcg
and budesonide (BUD)/formoterol (FORM) 400/12 mcg.
Results: For FEV1, FF/VI 100/25 mcg demonstrated >99% probability of non-inferiority to FP/SAL 500/50 mcg and
BUD/FORM 400/12 mcg using a 50 mL margin. For annual rate of moderate/severe exacerbations, FF/VI 100/
25 mcg demonstrated 73% and 77% probability of non-inferiority to FP/SAL 500/50 mcg and BUD/FORM 400/
12 mcg, respectively, using a 10% rate ratio margin. For SGRQ Total score, the corresponding probabilities of
non-inferiority were 99% and 98%, respectively, on a 2-unit margin. Significant covariate effects were identified:
increased age was associated with deterioration in FEV1 and reduced exacerbation frequency; shorter study
duration was associated with reduced exacerbation frequency.
Conclusions: FF/VI 100/25 mcg was comparable with corresponding doses of FP/SAL and BUD/FORM on lung
function and health status outcomes. Non-inferiority on moderate/severe exacerbation rate was not demonstrated to
the same degree of confidence, though observed rates were similar. Model limitations include a weak treatment
network for the exacerbation analysis and variability across the included studies. Our data support previous RCT
findings suggesting that the efficacy of FF/VI 100/25 mcg on lung function and health status in COPD is comparable
with twice-daily ICS/LABAs.
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Fluticasone furoate (FF)/vilanterol (VI) is an inhaled cor-
ticosteroid (ICS)/long-acting beta2 agonist (LABA) com-
bination maintenance therapy, approved in 2013 in the
United States, Canada and Europe at a strength of 100/
25 mcg (equivalent to an emitted dose from the inhaler
of 92/22 mcg) for chronic obstructive pulmonary disease
(COPD). Unlike established ICS/LABA combination
therapies, the 24-hour activity of both of its components
means that FF/VI is suitable for once-daily dosing. Sys-
tematic reviews have supported the long-term use of
LABAs and ICS/LABA combination therapies in COPD
[1,2]. In randomised controlled trials (RCTs) in patients
with COPD, FF/VI has consistently demonstrated an ac-
ceptable safety profile, similar to that of the comparable
strength of the established twice-daily combination ther-
apy fluticasone propionate (FP)/salmeterol (SAL), and
been found to be well tolerated [3,4].
Several RCTs have examined the efficacy of FF/VI vs
its components [5], placebo and components [6,7], pla-
cebo [8,9], tiotropium [10] or FP/SAL [3] in COPD. In
12-week double-blind, double-dummy head-to-head
studies, the efficacy of once-daily FF/VI 100/25 mcg in
improving lung function and health status in patients
with COPD was shown to be similar to that of twice-
daily FP/SAL 500/50 mcg [3,4]. The efficacy of once-
daily FF/VI has not, at the time of writing, been directly
compared in an RCT with that of ICS/LABA combin-
ation therapies other than FP/SAL, such as budesonide
(BUD)/formoterol (FORM) 400/12 mcg (equivalent to
an emitted dose of 320/9 mcg). However, the observed
difference in efficacy between FF/VI and VI in patients
with COPD is consistent with that reported between
other ICS/LABA combinations and their LABA mono-
component [5,11,12], suggesting comparability of FF/VI
with other ICS/LABA combination treatments in COPD.
We sought to investigate the relative treatment efficacy of
FF/VI 100/25 mcg in COPD compared with alternative li-
censed ICS/LABA combination therapies, using a mixed
treatment comparison (MTC) approach. This model-based
methodology provides a means of estimating the relative ef-
ficacy of treatments that have not been directly compared
in an RCT, and broadens the evidence base for those treat-
ments which have already been compared in head-to-head
studies. We conducted an MTC utilising a Bayesian,
hierarchical model, combining data from separate RCTs
identified through a systematic literature review to make
inferences about the relative treatment efficacy of FF/VI
100/25 mcg compared with FP/SAL 250/50 mcg and
BUD/FORM 400/12 mcg. RCTs included in the model in-
volved a range of comparators; all included at least one
ICS/LABA therapy. Three clinically relevant outcomes
were examined: lung function as assessed by forced ex-
piratory volume in one second (FEV1), exacerbations andhealth-related quality of life (Jansen, 2008). The primary
focus of the analyses was on non-inferiority.Methods
Systematic literature review
A systematic literature review was conducted to identify
Phase III and Phase IV parallel-group RCTs of any ICS/
LABA maintenance therapies vs any drug comparator(s).
Studies of >8 weeks duration, in ≥10 patients aged ≥12 years,
with an established diagnosis of COPD at any severity war-
ranting treatment (defined as % predicted forced expiratory
volume in one second [FEV1] ≤80%), who were receiving
ICS or ICS/LABA maintenance therapy at randomisation,
were included. Studies examining only short-acting beta
agonists or short-acting muscarinic antagonists aimed
at symptom control were excluded. RCTs of FF/VI were
identified internally using the same criteria.
Studies were identified through the systematic searching
of clinical publication databases and clinical trial registers
(Additional file 1). Additionally, references in retrieved ar-
ticles and relevant systematic reviews were checked for
further studies that might fulfil the inclusion criteria. No
date limits were applied to the searches.Outcome assessment
The outcomes assessed were: change from baseline in FEV1
(the outcome of primary interest); annual rate of moderate
exacerbations (worsening symptoms of COPD that required
treatment with oral corticosteroids and/or antibiotics) or
severe exacerbations (worsening symptoms of COPD that
required an emergency room visit and/or in-patient hospi-
talisation); and change from baseline in St George’s Respira-
tory Questionnaire (SGRQ or SGRQ-C) Total score.
The effect of treatment on lung function was assessed
through reporting of change from baseline in FEV1. Because
of the widely-accepted clinical importance of airflow limita-
tion in COPD [13,14], FEV1 was considered the outcome of
primary interest from the MTC. Exacerbation rates and
SGRQ (a health status questionnaire with three compo-
nents: symptoms, activity and impact on daily life) were the
other outcomes of interest.
For each outcome, studies identified through the sys-
tematic literature review were included in the MTC if they
reported the precise endpoint or sufficient calculable in-
formation in a suitable format. For exacerbations, the
reporting of either the rate or number of moderate/severe
exacerbation [15], in combination with number of pa-
tients, study duration and (for number of exacerbations
only) number of withdrawals, was required for inclusion
in the analysis. All treatment arms in each included study
were included in the MTC, with one exception where data
provided for the placebo arm were insufficient for the
study’s inclusion in the exacerbations analysis [16].
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were chosen on the basis of prior comparative studies in
COPD. Margins for change from baseline in FEV1 and in
SGRQ Total score represent approximately half of the ac-
cepted minimum clinically important difference (MCID)
of approximately 100 mL and 4 units, respectively [17,18],
and both the 2- and 3-unit thresholds were also examined
for SGRQ Total score. For exacerbations, annual rate
reduction margins of 10% and 20% were examined.
Exacerbation history is a very strong predictor of an indi-
vidual’s risk of future exacerbations [19]. As such, to maxi-
mise comparability, the main analysis of exacerbation rate
data was performed using data from only those studies
that required an explicit history of exacerbation for
study entry.Modelling strategy
The MTC modelling approach used for evidence synthesis
accounts for variability across studies through parameter-
isation of the study effect to estimate relative treatment ef-
fects. The Bayesian approach [20-22] was decided upon
prior to commencement of the systematic literature re-
view. This methodology allows for inference from weak or
disconnected treatment networks [23].
For each of the three outcomes, a hierarchical model was
created whereby the effect of each included study α was
modelled with a distribution αS~N(μ, τ
2). The two parame-
ters μ and τ were then modelled with second-level hyper-
priors and a posterior distribution created. Treatment effects
were then modelled separately as single parameters with
independent prior distributions, enabling the derivation of
probabilistic comparisons between treatments together with
credible intervals (CrI) for the differences in effect sizes.
For continuous outcomes (change from baseline in
FEV1 and SGRQ Total score), the mean treatment ef-
fects were modelled with Normal distributions: Y ~
N(αs + θt + βZ, σ
2) with non-informative prior σ2αeInverse−
Gamma 0:001; 0:001ð Þ and hyperpriors μs~N(0, 102) and
τ2 ~ Inverse −Gamma(0.001, 0.001). The parameters α and
θ represent, respectively, the studies included in the ana-
lysis, and the treatment regimen effects. The Z’s represent
the covariates and the β’s represent the coefficients (covar-
iate effects). Each treatment effect was modelled inde-
pendently with the flat prior distribution N(0, 1002).
Annual moderate/severe exacerbation rates were mod-
elled using a Poisson distribution: Exac ~ Poisson(Rate*per-
son-years), in which log(rate) = αs + θt + βZ, requiring input
of the number of moderate/severe exacerbation events and
the number of person-years of follow-up. Priors and model
parameters for study effects and treatment effects for this
outcome were defined as for the other three outcomes, as
was the distribution of study effects, with hyperpriors
μs~N(0, 10
2) and τ2 ~ Inverse −Gamma(0.001, 0.001).Exacerbation rate was defined as the number of exacer-
bation events divided by person-years of follow-up.
Person-years of follow-up were computed directly if both
the rate and number of events were available or, if neither
were available, the person-years were estimated. When es-
timated, patients not lost to follow-up were assumed to
have had complete (100%) follow-up. Patients lost to
follow-up were assumed to have 50% of the possible
follow-up. When the number of events was not reported,
the rate and estimated person-years of follow-up were
used to estimate the number of moderate/severe exacerba-
tion events. The priors and hyperpriors were similar to the
other analyses.
Covariates were included in the models using a fixed-
effects approach; a coefficient was created for each covari-
ate. The coefficients were modelled independently with
each having a flat prior distribution of N(0,102). The follow-
ing covariates were included in the ‘full-covariate’ models:
study duration, age, gender, smoking status, percent pre-
dicted FEV1 and exacerbation history. The continuous
covariates – age, gender and smoking history – were nor-
malised. Specifically, age was normalised by subtracting
60 years of age; the resulting covariate is “Age – 60”.
Gender is represented as the percentage of males in a treat-
ment arm. Gender was normalised by subtracting 75% from
the treatment arm population of males, thus the covariate
is “proportion male – 0.75”. Smoking status is represented
as the percentage of current smokers in a treatment arm.
Smoking status was normalised by subtracting 50% from
the treatment arm population of current smokers, thus the
covariate is “proportion smokers – 0.5”. The categorical co-
variates – % predicted FEV1 at baseline, exacerbation his-
tory and study length – had designated reference groups of
mean % predicted FEV1 50– ≤ 70%; ≥1 exacerbation in
previous year; and study duration 40–60 weeks, re-
spectively. Findings from a reduced model including
only one covariate (study duration) are provided in
Additional file 1: e-Table S4.
For each outcome, model fit was evaluated by asses-
sing the standardised residual, i.e. the difference between
the model-estimated values and observed values divided
by the estimated standard deviation.
All analyses were conducted using standard Markov
Chain Monte Carlo methodology, utilising adaptive
Metropolis-Hastings steps [24] where applicable, and were
performed using custom software written in ANSI-
standard Fortran (Berry Consultants LLC, Austin, TX).
The software used was independently validated with dupli-
cate code written in R (R Development Core Team,
Vienna, Austria).
Sensitivity analysis
A sensitivity analysis in which studies that were excluded
from the primary analysis were added to the model was
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rate outcome. Six additional studies in which there were no
explicit requirements for a history of patient exacerbations
were included in the sensitivity analysis network. A second
sensitivity analysis of the exacerbation rate data used a sub-
set of the network including only those studies for which
reported exacerbation rates were adjusted for follow-up.
For the SGRQ outcome, one sensitivity analysis was per-
formed where two studies were excluded from the network:
one was removed because data values were markedly differ-
ent from those in other studies in the model, and the other
study was removed because baseline SGRQ values were
much higher than for other studies in the model.
Assessment of alternative modelling approaches
Two post-hoc analyses using alternative modelling ap-
proaches were conducted in order to evaluate the extent
to which outcomes were susceptible to the primary model
chosen. The same input data sets were used in all analyses.
One set of analyses utilised the frequentist approach using
a random effect model with fixed study and treatment ef-
fects and random study x treatment interaction. R soft-
ware (lme4 package) was used for effect estimation with
lmer function used for FEV1 and SGRQ and glmer for ex-
acerbations. The second set of analyses was based on pair-
wise contrasts, but with no covariate adjustment, and
conducted using a Bayesian random effects model in
geMTC software [25] running WinBUGS [26]. As geMTC
did not enable automated analyses of rates with Poisson
distributions, exacerbation rates were approximated as
continuous variables, comparing rate differences rather
than rate ratios. In the validation analyses, point estimates
with confidence or credible intervals were calculated, with
the frequentist analyses also reporting p-values.
Results
Study selection
Fifty-nine unique studies were considered for inclusion
in the MTC (Figure 1). A total of 33 trials were included
in the primary analysis: of these, 28 were included in the
analysis of the outcome of primary interest of change
from baseline in FEV1; 20 were included in the SGRQ
analysis; and 15 were included in the exacerbation rates
analysis (Additional file 1: e-Table S1). The studies and
treatment arms included in the MTC are summarised in
Table 1. Reasons for exclusion of studies from each ana-
lysis are outlined in the Additional file 1: e-Appendix.
Comparison of clinical efficacy of FF/VI with twice-daily
ICS/LABA combinations
Change from baseline FEV1
FF/VI 100/25 mcg once daily was associated with an esti-
mated mean (±SD) 28 ± 38 mL absolute improvement from
baseline, higher than the estimated mean of 5 ± 40 mL forFP/SAL 500/50 mcg twice daily and the estimated mean
of 1 ± 42 mL for BUD/FORM 400/12 mcg twice daily
(Additional file 1: e-Table S2). On average, a decrease
from baseline (−123 ± 39 mL) was seen with placebo.
Hence, all three selected ICS/LABA combination ther-
apies produced improvements in FEV1 vs placebo that
exceeded the MCID of 100 mL [17] (Figure 2).
Based on a non-inferiority margin of approximately half
the MCID (i.e. 50 mL), FF/VI 100/25 mcg demonstrated
>99% probability of non-inferiority to both FP/SAL 500/50
mcg and BUD/FORM 400/12 mcg (Table 2). A significant
covariate effect of age was seen; therefore a smaller change
from baseline in FEV1 can be expected in studies enrolling
older patients on average (Additional file 1: e-Table S3).
Annual moderate/severe exacerbation rates
Marked decreases relative to placebo (placebo rate normal-
ised to 1.0) in annual moderate/severe exacerbation rates
were observed for FF/VI 100/25 mcg (0.62), FP/SAL 500/
50 mcg (0.66) and BUD/FORM 400/12 mcg (0.71). The CrI
for FF/VI 100/25 mcg (0.285, 1.181) was very wide, result-
ing in its being found statistically inseparable from placebo,
whereas BUD/FORM 400/12 mcg (CrI: 0.638, 0.795) and
FP/SAL 500/50 mcg (CrI: 0.555, 0.790) were statistically
separable from placebo (Additional file 1: e-Table S2).
Based on a non-inferiority margin representing an an-
nual event rate ratio reduction of 10%, FF/VI 100/25 mcg
demonstrated 73% probability of non-inferiority to FP/
SAL 500/50 mcg and 77% probability of non-inferiority to
BUD/FORM 400/12 mcg. On a less stringent 20% rate ra-
tio margin, FF/VI 100/25 mcg has 80% probability of non-
inferiority to FP/SAL 500/50 mcg and 84% probability of
non-inferiority to BUD/FORM 400/12 mcg (Table 2).
Significant covariate effects of age and study duration were
observed: studies that enrolled older patients showed
slightly lower average exacerbation rates, and reduced ex-
acerbation rates were seen in shorter duration studies
(Additional file 1: e-Table S3).
Change from baseline SGRQ total score
FF/VI 100/25 mcg, FP/SAL 500/50 mcg and BUD/
FORM 400/12 mcg were all associated with significant
improvement in estimated mean SGRQ score relative to
placebo. The mean improvement observed with FF/VI
100/25 mcg (−4.599 units) exceeded the MCID of 4
units and was numerically greater than that seen with
FP/SAL 500/50 mcg (−3.278) or BUD/FORM 400/12
mcg (−3.635) (Additional file 1: e-Table S2).
Based on a non-inferiority margin of 2 units (half the
MCID), FF/VI 100/25 mcg demonstrated 99% probability of
non-inferiority to FP/SAL 500/50 mcg and 98% probability
of non-inferiority to BUD/FORM 400/12 mcg for change
from baseline SGRQ score. Using a 3-unit margin, FF/VI
had >99% probability of non-inferiority to both FP/SAL and
FF 100 
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Figure 1 (See legend on next page.)
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Figure 1 Network of treatments connected by studies for each outcome of interest. A: change from baseline FEV1, L; B: annual rate of
exacerbations; C: change from baseline SGRQ Total score. Note: All stated nominal doses are mcg. Connecting lines represent studies included in the
model that directly compare the two treatments. The thickness of the line is proportional to the number of studies comparing the two treatments.
BDP = beclomethasone dipropionate, BID = twice daily, BUD = budesonide, FORM = formoterol, FF = fluticasone furoate, FP = fluticasone propionate,
MMF =mometasone furoate, QD = once daily, SAL = salmeterol, THEO= theophylline, TIO = tiotropium, VI = vilanterol.
Stynes et al. Respiratory Research  (2015) 16:25 Page 6 of 11BUD/FORM. No significant covariate effects on the change
from baseline SGRQ Total score outcome were identified in
the main analysis.
Sensitivity analysis
A sensitivity analysis of an enlarged network (Additional
file 1: e-Figure S1) was conducted for the exacerbations





Change from baseline in FEV1 28 (85)
Annual rate of moderate/severe exacerbations 15 (45)
Change from baseline in total SGRQ 20 (61)
Exacerbation history
At least 1 14 (42)
At least 2 3 (9)





Mean age reported 63.79
Mean proportion male 0.73
Mean proportion current smokers 0.46
Note: All stated nominal doses are mcg.
BDP = beclomethasone dipropionate, BID = twice daily, BUD = budesonide, FORM = f
furoate, FP = fluticasone propionate, MMF =mometasone furoate, QD = once daily, S
TIO = tiotropium, VI = vilanterol.patients to have an explicit history of exacerbations were
added to the primary analysis network of 15 studies. The
findings of this sensitivity analysis (Additional file 1: e-Table
S5) were similar to those of the primary analysis, and the
CrIs for comparisons of FF/VI 100/25 mcg remained wide;
thus, it was not possible to draw conclusions on non-
inferiority of FF/VI 100/25 mcg on exacerbation rate from
the sensitivity analysis. Separate sensitivity analyses of thethe mixed treatment comparison analysis
N (%)
Total treatment arms 104
Treatments
Placebo 14 (13)
FF/VI 50/25 QD 3 (3)
FF/VI 100/25 QD 7 (7)
FF/VI 200/25 QD 3 (3)
FF 100 QD 2 (2)
FF 200 QD 1 (1)
VI 25 QD 4 (4)
FP/SAL 250/50 BID 8 (8)
FP/SAL 500/50 BID 14 (13)
FP/SAL 500/50 BID + TIO18 QD 1 (1)
SAL 50 BID 10 (10)
SAL 50 BID + theophylline 1 (1)
FP 250 BID 1 (1)
FP 500 BID 3 (3)
FP 500 BID + TIO 18 QD 1 (1)
BUD/FORM 160/9 BID 3 (3)
BUD/FORM 400/12 BID 9 (9)
BUD 160 BID 1 (1)
BUD 320 BID 3 (3)
FORM 9 BID 8 (8)
MMF 400 BID 1 (1)
MMF/FORM 200/10 BID 1 (1)
MMF/FORM 400/10 BID 1 (1)
TIO 18 QD 3 (3)
BDP(extra fine)/FORM 200/12 BID 1 (1)
ormoterol, FEV1 = forced expiratory volume in one second, FF = fluticasone
AL = salmeterol, SGRQ = St George’s Respiratory Questionnaire,
Figure 2 (See legend on next page.)
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Figure 2 Change from baseline versus placebo estimated using the full covariate model for selected treatments. A: FEV1; B: rate ratio of
moderate/severe exacerbations*; C: Total SGRQ. *Derived from studies in which patients were required to have an explicit exacerbation history at
baseline. BUD = budesonide, CI = confidence interval, FEV1 = forced expiratory volume in one second, FF = fluticasone furoate, FORM = formoterol,
FP = fluticasone propionate, SAL = salmeterol, SGRQ = St George’s Respiratory Questionnaire, VI = vilanterol.
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for patients lost to follow-up reached similar conclusions to
the primary analysis (Additional file 1: e-Table S6). Findings
of a sensitivity analysis of the SGRQ outcome in which two
studies were excluded from the network were similar to
those of the primary analysis.
Assessment of alternative modelling approaches
The findings and details of the post-hoc analysis of alter-
native modelling approaches – specifically, a frequentist
analysis using a random effects model with fixed study
and treatment effects, and a pairwise contrast analysis –
are reported in Addional file 1: e-Table S7. The results
of these analyses showed that, where the application of
varied methodologies to the dataset was feasible, the re-
sults of analyses using these methodologies were consist-
ent with those of the primary MTC analysis.
Discussion
FF/VI 100/25 mcg represents the first once-daily ICS/
LABA combination approved in the United States, Canada
and Europe for the long-term maintenance treatment of
patients with COPD. We sought to compare the clinicalTable 2 Posterior probability of non-inferiority for FF/VI 100/
(full covariate model)
A: change from baseline FEV1
Treatment Comparator Mean
FF/VI 100/25 FP/SAL 500/50 0.023
FF/VI 100/25 BUD/FORM 400/12 0.027
B: annual rate of moderate/severe exacerbations†
Treatment Comparator Rate
FF/VI 100/25 FP/SAL 500/50 0.925
FF/VI 100/25 BUD/FORM 400/12 0.866
C: change from baseline SGRQ Total score
Treatment Comparator Mean
FF/VI 100/25 FP/SAL 500/50 −1.32
FF/VI 100/25 BUD/FORM 400/12 −0.96
Note: All stated nominal doses are mcg.
BUD = budesonide, Crl = credible interval, FORM = formoterol, FEV1 = forced expirato
S = salmeterol, SGRQ = St George’s Respiratory Questionnaire, VI = vilanterol.
*Other relevant ICS/LABA: FP/SAL 500/50 mcg and BUD/F 400/12 mcg.
†For studies in which patients were required to have an explicit exacerbation historefficacy of FF/VI 100/25 mcg with that of the twice-daily
ICS/LABA therapies FP/SAL 500/50 mcg and BUD/FORM
400/12 mcg. The comparative efficacy of FF/VI 100/25 mcg
and FP/SAL 500/50 mcg has previously been investigated
in head-to-head RCTs, and no significant treatment differ-
ence in terms of lung function was observed [3,4].
Using an MTC approach, we examined the probability
of non-inferiority of once-daily FF/VI 100/25 mcg to
corresponding strengths of twice-daily ICS/LABA com-
bination therapies – FP/SAL 500/50 mcg and BUD/
FORM 400/12 mcg – by combining data on clinical effi-
cacy outcomes from several RCTs. The selected compar-
isons are presented on the basis of the robustness of the
networks and the current relevance of these treatments
in clinical practice. All three ICS/LABA combination
therapies have been shown to be associated with im-
provement in these outcomes vs placebo in RCTs.
We applied a Bayesian hierarchical MTC model to com-
bine existing data from RCTs conducted in patients with
COPD, that examined at least one ICS/LABA comparator.
Broad-scope searches were used to identify as many stud-
ies potentially suitable for inclusion in the MTC as pos-
sible. In an effort to maximise comparability of included25 mcg versus other relevant ICS/LABA*





ratio (95% CrI) Probability of non-inferiority margin
(event rate ratio)
0.10 0.20
(0.451, 1.734) 73% 80%
(0.396, 1.664) 77% 84%
difference, units (95% CrI) Probability of non-inferiority margin
(units)
2 3
1 (−3.955, 1.313) 99% >99%
4 (−3.897, 1.970) 98% >99%
ry volume in one second, FF = fluticasone furoate, FP = fluticasone propionate,
y at entry.
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Studies were required to be Phase III or IV parallel-group
RCTs examining at least one ICS/LABA maintenance
therapy, to report usable data for at least one of the three
specified MTC efficacy endpoints, to have included suffi-
cient patients (≥10 patients aged ≥12 years) and to have
been of sufficient duration (>8 weeks). Subsequently, add-
itional endpoint-specific inclusion criteria were applied as
appropriate for each endpoint. Following the modelling of
the observed data, the Bayesian methodology allowed us
to utilise the posterior distribution to provide a probabilis-
tic estimate of non-inferiority for FF/VI in comparison to
other ICS/LABA maintenance therapies [27].
Non-inferiority margins are not well established for
COPD outcomes, and were chosen prior to the com-
mencement of any data analysis with reference to public
recommendations of the US Food and Drug Administra-
tion [28] and the European Medicines Agency (CBG-MEB,
2008) and to threshold values used for assessment of drug
therapy non-inferiority in previous clinical trials in COPD.
For FEV1, the selection of a conservative 50 mL margin
was informed by the well-accepted MCID of 100–140 mL
[17,29] and the use of this value in previous non-
inferiority studies of tiotropium [30,31]. Non-inferiority
margins reflecting exacerbation event rate ratios of 10%
and 20% were selected on the basis of findings from the
ISOLDE trial of ICS vs placebo [32] and a Cochrane ana-
lysis of nine ICS/LABA vs ICS studies [33] in which rate
reductions of 24% and 25%, respectively, were reported.
For SGRQ, non-inferiority limits of 2 and 3 scoring units
were used; these margins represent half and three quarters
of the accepted MCID of 4 units [18] and of the observed
overall difference between ICS/LABA and placebo in the
TORCH trial [34]. The selection of margins that are
narrow relative to the MCID increases the difficulty of
demonstrating non-inferiority of compared treatments;
they are therefore regarded as conservative. It is, however,
important to note that a finding of a low probability of
non-inferiority does not imply lack of comparability or
inferiority of the intervention.
Based on these conservative margins, the findings from
our MTC analysis support previously-reported RCT find-
ings and indicate that there is a high probability that FF/VI
100/25 mcg is non-inferior to FP/SAL 250/50 mcg and
BUD/FORM 400/12 mcg on lung function (FEV1) and
health status (SGRQ) outcomes of interest. The analysis of
exacerbation rate data was inconclusive owing to insuffi-
cient data and the consequent weakness of the network for
this outcome, resulting in wide CrI.
The data limitations were primarily a consequence of
the limited number of RCTs evaluating the ICS/LABA
treatments of interest that met the inclusion criteria and
were therefore available for inclusion in the MTC. In par-
ticular, the exacerbations network was weak with respectto FF/VI, as only one 12-week study of FF/VI 100/25 mcg
connected the FF/VI studies with the rest of the treatment
network and this particular study reported a substantially
lower annual moderate/severe exacerbation rate com-
pared with other studies in the network. In addition, this
single study link was the only study of less than 20 weeks’
duration. The model accounts for the potential effect of
the study’s short length on the reported exacerbation rate;
however, this inevitably impacts the informative value of
this study, contributing further to the weakness of the ex-
acerbation rates network. As a consequence, the evidence
available does not allow for definitive statements regarding
these comparisons on this outcome of interest.
In a sensitivity analysis of the exacerbation event rate ra-
tio MTC, the criteria for inclusion of studies in the net-
work were relaxed and studies which did not have an
inclusion criterion of requiring an explicit history of exac-
erbations were included. The sensitivity analysis network
included additional treatments, but the strength of the
comparisons of FF/VI 100/25 mcg with corresponding
doses of FP/SAL and BUD/FORM was not substantially
improved and the CrIs for the non-inferiority analysis
remained wide. The post-hoc assessment of alternative
modelling approaches showed that the findings of the lung
function and health status MTCs were consistent upon
the application to the data of other methodologies, includ-
ing a frequentist approach.
Variability in study design also impacted the precision of
model estimates. The studies included in our MTC were
heterogeneous in population and region. Furthermore,
there is a substantial degree of inconsistency in the defini-
tions of and measurement methodologies used to assess re-
spiratory clinical outcomes such as FEV1 [35]. Some RCTs
report exacerbation rates adjusted for patients lost to
follow-up while other studies lack information on follow-
up and report only the number of exacerbations. We
attempted to address these issues in our inclusion criteria
and sought to include all comparable patient populations.
An in-built assumption of the model – that could poten-
tially be confounded by study heterogeneity with regard to
aspects of the patient population and the region(s) in which
the study was conducted – is that treatment effects are
consistent across studies. As far as possible, over-dispersion
arising as a consequence of this large study-to-study vari-
ability was observed in the distribution and accounted for
through the incorporation of heterogeneity factors at the
study level of the hierarchy. However, the degree to which
heterogeneity could be accounted for was limited by the
amount of data available and unavailability of patient-level
information about covariates and outcomes.
By incorporating covariates into the model at the study
level, we assessed whether study and population variability
in covariates such as duration, average age and exacerbation
history could have impacted the suitability for comparison
Stynes et al. Respiratory Research  (2015) 16:25 Page 10 of 11of the studies included in the MTC. Age had a significant
covariate effect on FEV1, which is to be expected since
COPD is a disease characterised by progressive deterior-
ation in lung function. Since older patients would be
expected to have poorer baseline lung function than youn-
ger patients, we would expect to see smaller changes in
FEV1 in studies recruiting a patient population with a
higher average age. The observation that exacerbation
rates were typically lower in shorter studies could also be
due to the progressive deterioration in lung function with
COPD, which is associated with increased exacerbation
rates [15]. However, the finding of a significant covariate
relationship of older average age with lower exacerbation
rates is perhaps counterintuitive. One possible explanation
is that older patients may have been selected from gener-
ally better-controlled patient populations.
MTC is an established approach to the synthesis of indir-
ect and direct evidence to make comparisons of and draw
conclusions around the relative efficacy of multiple treat-
ments in a single model. In a previous MTC, published in
2009, data from 43 RCTs were analysed with respect to ex-
acerbation, mortality and study withdrawal rates [36] in
COPD. Relative to alternative treatment modalities, ICS/
LABA combination therapy was found to have the greatest
positive effect on outcomes. The results of another MTC,
examining exacerbation rates using data from 26 trials, also
indicated that combination therapies may offer a thera-
peutic advantage over monotherapies [37]. To our know-
ledge, our data are the first MTC findings to be reported
on treatment effects on lung function and health-related
quality of life in COPD.
Conclusions
The findings of the MTC suggest that the efficacy of
once-daily FF/VI 100/25 mcg in COPD is broadly com-
parable to that of twice-daily FP/SAL 500/50 mcg and
BUD/FORM 400/12 mcg for lung function and health-
related quality of life outcomes in a clinical trial setting.
It should be borne in mind that the MTC findings are
obtained through the analysis of outcomes from RCTs
and any potential efficacy benefits that may be derived
from once- vs twice-daily dosing in real-world clinical
practice may not be reflected in these data.
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